The European Union has approved daraxonrasib combined with chemotherapy for previously treated metastatic pancreatic cancer after the regimen controlled disease in 90.2 percent of trial participants, the European Medicines Agency announced Tuesday.
The accelerated approval follows data presented at the EORTC-NCI-AACR Symposium in Barcelona showing that adding the RAS inhibitor to standard chemotherapy shrank tumors in 60.7 percent of patients and produced complete radiographic responses in 8.2 percent, De Morgen reported. Median progression-free survival reached 12.8 months, nearly double the historical benchmark for this patient population.
“This comes closest to a cure,” lead investigator Wungki Park, MD, PhD, of Memorial Sloan Kettering Cancer Center, told LBC Radio. “We see not only a higher percentage of tumors responding, but the response is deeper and disease control lasts almost twice as long.”
The EMA’s Committee for Medicinal Products for Human Use issued its positive opinion in just over 100 days, roughly half the standard 210-day review timeline.
- Daraxonrasib targets the mutated KRAS protein that drives more than 90 percent of pancreatic tumors, effectively jamming a stuck “on” switch for cancer growth.
- In an early study, adding this pill to chemotherapy stopped tumor growth in 90.2 percent of patients and shrank tumors in 60.7 percent.
- Regulators in Europe and the U.S. have fast-tracked access for patients who have already received at least one prior therapy.
KRAS mutations act as a molecular ignition switch locked in the “on” position, driving uncontrolled cellular proliferation. For decades the protein’s smooth surface thwarted drug designers.
Daraxonrasib belongs to a new class of RAS(ON) inhibitors that bind the active, GTP-bound conformation of the mutant protein, blocking downstream MAPK pathway signaling. The trial combined the oral inhibitor with nab-paclitaxel and gemcitabine, the current standard backbone for previously treated metastatic disease.
Investigators cautioned that complete radiographic response does not equate to cure; microscopic residual disease likely persists. The study was single-arm and relatively small, lacking a randomized control arm.
The EMA’s accelerated assessment procedure, reserved for medicines of major public health interest, compressed the scientific review to roughly 100 days. Conditional marketing authorization requires Revolution Medicines to submit confirmatory Phase III data.
The European Medicines Agency, founded in 1995 to harmonise national regulatory work across the EU, moved its headquarters from London to Amsterdam in March 2019 following the United Kingdom’s withdrawal from the bloc. Its Committee for Medicinal Products for Human Use, which issued the positive opinion on daraxonrasib, operates under a standard 210-day review clock that pauses whenever the applicant must supply additional data.
Daraxonrasib is indicated only for adults with KRAS-mutated metastatic pancreatic adenocarcinoma who have progressed on prior systemic therapy. It is contraindicated in patients with severe hepatic impairment (Child-Pugh C) and during pregnancy. Clinicians should monitor liver function tests, complete blood counts, and creatinine kinase levels regularly. Patients experiencing new or worsening dyspnea, fever, severe diarrhea, or signs of interstitial lung disease should seek immediate medical evaluation.
- Park W, et al. Presented at EORTC-NCI-AACR Symposium, Barcelona, 2026.
- European Medicines Agency. CHMP summary of positive opinion for daraxonrasib. 2026.
- U.S. Food and Drug Administration. Accelerated approval letter for daraxonrasib. 2026.
- Revolution Medicines. Corporate pipeline and clinical trial disclosures. 2026.
Worth a look
- MYC Inhibitor OMO-103 Targets Cancer Directly and via Immune System, Mouse Data Show
- Constanze Lohse: These Three Nutrients Recommended for Over-60s
- Argentina Senate Approves Foreign-Flag Cabotage Bill, Patent Treaty Accession (world-today-journal.com)
- Jax Taylor Reveals Kidney Cancer Surgery; Kelce, Bure Podcast Comments (archynewsy.com)